RADIOIODINE ABLATION OF RESIDUAL TISSUE IN THYROID-CANCER - RELATIONSHIP BETWEEN ADMINISTERED ACTIVITY, NECK UPTAKE AND OUTCOME

被引:36
作者
LOGUE, JP [1 ]
TSANG, RW [1 ]
BRIERLEY, JD [1 ]
SIMPSON, WJ [1 ]
机构
[1] UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT RADIAT ONCOL,TORONTO M4X 1K9,ON,CANADA
关键词
D O I
10.1259/0007-1285-67-803-1127
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
A retrospective review was performed to evaluate the effectiveness of radioiodine in the ablation of residual thyroid tissue after surgery for differentiated thyroid cancer. 121 patients were treated at the Princess Margaret Hospital, Toronto, Canada between 1977 and 1989, with the activity of radioiodine determined empirically. Ablation of residual thyroid was determined by I-131 nuclear scans, using absent visible uptake (compared with background) as the criterion for successful ablation. 97 patients (80%) had successful ablation of residual thyroid tissue after the first administration of radioiodine. Patients with higher iodine uptake in the neck had a tendency to receive higher activities of I-131. There were no statistically significant differences in age, sex, type of surgery, initial iodine uptake in the neck and administered radioiodine activity between those successfully ablated and those that were not. Patients receiving less than 3.7 GBq (100 mCi) tended to have lower iodine uptake (<5% at 24 or 48 h), but their rate of thyroid ablation was just as high as those given 3.7 GBq or more. In order to take advantage of this, we have formalized our approach by deriving guidelines to the empiric determination of radioiodine activity based on the iodine uptake in the neck. Among the 11 patients treated with lobectomy only, the ablation rate was 64%. Although this was not significantly lower than for other forms of surgery, we continue to recommend completion thyroidectomy for this group of patients, if the goal of treatment is to ablate all thyroid tissue.
引用
收藏
页码:1127 / 1131
页数:5
相关论文
共 14 条
[1]  
BEIERWALTES WH, 1984, J NUCL MED, V25, P1287
[2]   NATURAL-HISTORY, TREATMENT, AND COURSE OF PAPILLARY THYROID-CARCINOMA [J].
DEGROOT, LJ ;
KAPLAN, EL ;
MCCORMICK, M ;
STRAUS, FH .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 71 (02) :414-424
[3]   COMPARISON OF 30-MCI AND 50-MCI DOSES OF I-131 FOR THYROID-ABLATION [J].
DEGROOT, LJ ;
REILLY, M .
ANNALS OF INTERNAL MEDICINE, 1982, 96 (01) :51-53
[4]   RADIONUCLIDE DIAGNOSIS AND THERAPY OF THYROID-CANCER - CURRENT STATUS-REPORT [J].
FREITAS, JE ;
GROSS, MD ;
RIPLEY, S ;
SHAPIRO, B .
SEMINARS IN NUCLEAR MEDICINE, 1985, 15 (02) :106-131
[5]  
JOHANSEN K, 1991, J NUCL MED, V32, P252
[6]   FAILURE OF LOW-DOSES OF I-131 TO ABLATE RESIDUAL THYROID-TISSUE FOLLOWING SURGERY FOR THYROID-CANCER [J].
KUNI, CC ;
KLINGENSMITH, WC .
RADIOLOGY, 1980, 137 (03) :773-774
[7]  
MASSAFERRI EL, 1981, AM J MED, V70, P511
[8]   RELATION BETWEEN EFFECTIVE RADIATION-DOSE AND OUTCOME OF RADIOIODINE THERAPY FOR THYROID-CANCER [J].
MAXON, HR ;
THOMAS, SR ;
HERTZBERG, VS ;
KEREIAKES, JG ;
CHEN, IW ;
SPERLING, MI ;
SAENGER, EL .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (16) :937-941
[9]   RADIOIODINE-131 IN THE DIAGNOSIS AND TREATMENT OF METASTATIC WELL DIFFERENTIATED THYROID-CANCER [J].
MAXON, HR ;
SMITH, HS .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1990, 19 (03) :685-718
[10]  
MAXON HR, 1992, J NUCL MED, V33, P132